Literature DB >> 10939305

Potential role of cannabinoids in Parkinson's disease.

J Sevcík1, K Masek.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder caused by a progressive loss of dopaminergic neurons of the substantia nigra, resulting from an oxidative stress. The lack of dopaminergic neurons is reflected by a disturbed balance of the neural circuitry in the basal ganglia. Cannabinoids might alleviate some parkinsonian symptoms by their remarkable receptor-mediated modulatory action in the basal ganglia output nuclei. Moreover, it was recently observed that some cannabinoids are potent antioxidants that can protect neurons from death even without cannabinoid receptor activation. It seems that cannabinoids could delay or even stop progressive degeneration of brain dopaminergic systems, a process for which there is presently no prevention. In combination with currently used drugs, cannabinoids might represent, qualitatively, a new approach to the treatment of PD, making it more effective.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10939305     DOI: 10.2165/00002512-200016060-00001

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  34 in total

1.  Reefer madness--the federal response to California's medical-marijuana law.

Authors:  G J Annas
Journal:  N Engl J Med       Date:  1997-08-07       Impact factor: 91.245

2.  Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity.

Authors:  M Shen; S A Thayer
Journal:  Mol Pharmacol       Date:  1998-09       Impact factor: 4.436

Review 3.  Neuroprotective therapeutic strategies. Comparison of experimental and clinical results.

Authors:  M Gerlach; P Riederer; M B Youdim
Journal:  Biochem Pharmacol       Date:  1995-06-29       Impact factor: 5.858

4.  Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission.

Authors:  A J Hampson; L M Bornheim; M Scanziani; C S Yost; A T Gray; B M Hansen; D J Leonoudakis; P E Bickler
Journal:  J Neurochem       Date:  1998-02       Impact factor: 5.372

5.  Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease.

Authors:  A H Schapira; V M Mann; J M Cooper; D Dexter; S E Daniel; P Jenner; J B Clark; C D Marsden
Journal:  J Neurochem       Date:  1990-12       Impact factor: 5.372

Review 6.  Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease.

Authors:  J M Brotchie
Journal:  Mov Disord       Date:  1998-11       Impact factor: 10.338

Review 7.  The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.

Authors:  S Fahn; G Cohen
Journal:  Ann Neurol       Date:  1992-12       Impact factor: 10.422

Review 8.  Determinants of neuronal vulnerability in neurodegenerative diseases.

Authors:  B M Morrison; P R Hof; J H Morrison
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

9.  The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons.

Authors:  S D Skaper; A Buriani; R Dal Toso; L Petrelli; S Romanello; L Facci; A Leon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

10.  Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats.

Authors:  R S Mansbach; C C Rovetti; E N Winston; J A Lowe
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

View more
  4 in total

Review 1.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

2.  Inhibition by anandamide of 6-hydroxydopamine-induced cell death in PC12 cells.

Authors:  Katarzyna Mnich; David P Finn; Eilis Dowd; Adrienne M Gorman
Journal:  Int J Cell Biol       Date:  2010-02-16

Review 3.  Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.

Authors:  Mariana Babayeva; Haregewein Assefa; Paramita Basu; Sanjeda Chumki; Zvi Loewy
Journal:  Parkinsons Dis       Date:  2016-12-05

Review 4.  Cannabinoids in health and disease.

Authors:  Natalya M Kogan; Raphael Mechoulam
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.